Levetiracetam Accord (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which plays a key role in neurotransmitter release. By modulating SV2A activity, the drug stabilises neuronal firing and reduces excessive excitability in the brain, thereby decreasing the likelihood of seizure events.

The specific dose of Levetiracetam Accord is determined by the prescribing clinician based on the patient’s age, weight, renal function, and seizure type. The prescriber will tailor the regimen to achieve optimal seizure control while minimizing side effects.

Safety data for levetiracetam in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levetiracetam offers a distinct mechanism (SV2A modulation) compared with many older antiepileptics that act on sodium channels or GABA receptors. It generally has fewer drug‑enzyme interactions, a relatively favorable side‑effect profile, and can be used as monotherapy or adjunct therapy, making it a versatile option in many treatment regimens.

Levetiracetam Accord should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in their original container, protect them from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Levetiracetam Accord is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with water and not crushed or chewed unless specifically instructed. Consistency in timing helps maintain stable blood levels.

Serious risks include severe allergic reactions (such as rash, swelling, or breathing difficulty), significant mood or behavioral changes (including depression or suicidal thoughts), and rare blood disorders that can lower white‑blood‑cell or platelet counts. Patients should seek immediate medical attention if any of these symptoms appear.

Levetiracetam Accord is contraindicated in individuals with known hypersensitivity to levetiracetam or any of its excipients. Caution is advised for patients with severe renal impairment, as dose adjustments may be required, and for those with uncontrolled psychiatric conditions due to potential mood effects.